News

Clinical Advisor19h
Cardiovascular Benefit Seen With Tirzepatide in Head-to-Head Trial
SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.
Eli Lilly’s weight loss drug most effective at preventing heart attacks and strokes: What new study means for Mounjaro users
Trial shows that risk of a major adverse cardiovascular event is eight per cent lower in people on new therapy ...
Clinical Trials Arena1d
Eli Lilly’s Mounjaro shows cardiovascular gains, but analysts underwhelmed
Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.